PharmaEssentia Corporation secures Japan approval for high-dose BESREMi regimen in polycythemia vera

Japan approves high-dose BESREMi regimen for polycythemia vera. Read the full analysis on safety, adoption, and what clinicians will watch next.

Japan approves high-dose BESREMi regimen for polycythemia vera. Read the full analysis on safety, adoption, and what clinicians will watch next.